Physiogenex, its subsidiary company Cardiomedex, and its partner CLEA Japan Inc., will be presenting their collaborative work at the ISN-World Congress of Nephrology, to be held March 30-April 2 in Bangkok, Thailand.
Dr. François Briand, our Director of Research and Business Development, will be presenting 2 studies dealing with the innovative SDT fatty rat, a new model to evaluate drugs targeting diabetic nephropathy, during the poster sessions (5pm-6pm) on March the 31st and April the 1st:
LIRAGLUTIDE IMPROVES BOTH DIABETIC NEPHROPATHY AND CARDIOMYOPATHY IN THE SDT FATTY RAT, A CARDIORENAL MODEL OF TYPE 2 DIABETES
HIGH FAT/HIGH SUCROSE FEEDING AGGRAVATES KIDNEY LESIONS IN THE SPONTANEOUSLY DIABETIC TORII FATTY RAT, AN OBESE TYPE 2 DIABETIC MODEL OF NEPHROPATHY
Our collaborators from CLEA Japan Inc. Mr. Tsubaki (Business Development) and the SDT fatty rat expert Dr. Masami Shinohara will be also present at the poster session to answer attendees’ questions about our unique preclinical model of type 2 diabetes and related comorbidities.
Feel free to contact us if you wish to set-up an appointment with Dr. Briand and/or discuss your drug development projects with us.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.